Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice

医学 睾酮(贴片) 雄激素剥夺疗法 雄激素 临床实习 游离睾酮 内科学 内分泌学 泌尿科 性激素结合球蛋白 激素 物理疗法 前列腺癌 癌症
作者
Rashid K. Sayyid,Abdallah Sayyid,Zachary Klaassen,Kamel Fadaak,Hanan Goldberg,Thenappan Chandrasekar,Ardalan E. Ahmad,Ricardo Leão,Nathan Perlis,Karen Chadwick,Robert J. Hamilton,Girish S. Kulkarni,Antonio Finelli,Alexandre R. Zlotta,Neil Fleshner
出处
期刊:The Journal of Urology [Lippincott Williams & Wilkins]
卷期号:199 (1): 251-256 被引量:5
标识
DOI:10.1016/j.juro.2017.07.078
摘要

No AccessJournal of UrologyAdult Urology1 Jan 2018Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice Rashid K. Sayyid, Abdallah K. Sayyid, Zachary Klaassen, Kamel Fadaak, Hanan Goldberg, Thenappan Chandrasekar, Ardalanejaz Ahmad, Ricardo Leao, Nathan Perlis, Karen Chadwick, Robert J. Hamilton, Girish S. Kulkarni, Antonio Finelli, Alexandre R. Zlotta, and Neil E. Fleshner Rashid K. SayyidRashid K. Sayyid Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada Department of Surgery, Section of Urology, Medical College of Georgia, Augusta University, Augusta, Georgia More articles by this author , Abdallah K. SayyidAbdallah K. Sayyid Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Zachary KlaassenZachary Klaassen Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada Department of Surgery, Section of Urology, Medical College of Georgia, Augusta University, Augusta, Georgia More articles by this author , Kamel FadaakKamel Fadaak Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Hanan GoldbergHanan Goldberg Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Thenappan ChandrasekarThenappan Chandrasekar Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Ardalanejaz AhmadArdalanejaz Ahmad Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Ricardo LeaoRicardo Leao Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Nathan PerlisNathan Perlis Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Karen ChadwickKaren Chadwick Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Robert J. HamiltonRobert J. Hamilton Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Girish S. KulkarniGirish S. Kulkarni Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Antonio FinelliAntonio Finelli Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Alexandre R. ZlottaAlexandre R. Zlotta Department of Urology, Mt. Sinai Hospital, Toronto, Ontario, Canada More articles by this author , and Neil E. FleshnerNeil E. Fleshner Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.07.078AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determined whether men on continuous androgen deprivation therapy who achieve testosterone less than 0.7 nmol/l demonstrate subsequent testosterone elevations during followup and whether such events predict worse oncologic outcomes. Materials and Methods: We evaluated a random, retrospective sample of 514 patients with prostate cancer treated with continuous androgen deprivation therapy in whom serum testosterone was less than 0.7 nmol/l at University Health Network between 2007 and 2016. Patients were followed from the date of the first testosterone measurement of less than 0.7 nmol/l to progression to castrate resistance, death or study period end. Study outcomes were the development of testosterone elevations greater than 0.7, greater than 1.1 and greater than 1.7 nmol/l, and progression to a castrate resistant state. Survival curves were constructed to determine the rate of testosterone elevations. Multivariate Cox regression analysis was done to assess whether elevations predicted progression to castrate resistance. Results: Median patient age was 74 years and median followup was 20.3 months. Within 5 years of followup 82%, 45% and 18% of patients had subsequent testosterone levels greater than 0.7, greater than 1.1 and greater than 1.7 nmol/l, respectively. In 96% to 100% of these patients levels less than 0.7 nmol/l were subsequently reestablished within 5 years. No patient baseline characteristic was associated with elevations and elevations were not a significant predictor of progression to a castrate resistant state. Conclusions: Men on continuous androgen deprivation therapy in whom initial testosterone is less than 0.7 nmol/l frequently show subsequent elevations in serum testosterone. Such a development should not trigger an immediate response from physicians as these events are prognostically insignificant with regard to oncologic outcomes. Levels are eventually reestablished at less than 0.7 nmol/l. References 1 : Role of luteinising hormone releasing hormone (LHRH) agonist in the management of prostate cancer. Eur Urol2005; 4: 4. Google Scholar 2 : Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate—1941. J Urol2002; 168: 9. Link, Google Scholar 3 : EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol2014; 65: 467. Google Scholar 4 : EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol2017; 71: 630. Google Scholar 5 : Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormone-binding globulin. Clin Chem1987; 33: 1372. Google Scholar 6 : Reassessment of the definition of castrate levels of testosterone: implications for clinical decision-making. Urology2000; 56: 1021. Crossref, Medline, Google Scholar 7 : Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol2007; 178: 1290. Link, Google Scholar 8 : Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol2015; 33: 1151. Google Scholar 9 : Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int2009; 103: 322. Google Scholar 10 : Free testosterone during androgen deprivation therapy predicts castration-resistant progression better than total testosterone. Prostate2007; 77: 114. Google Scholar © 2018 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byTremblay S, Summers-Trasiewicz L, Pouliot F, Crook J, Ding K, Klotz L and Toren P (2021) Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate CancerJournal of Urology, VOL. 206, NO. 5, (1166-1176), Online publication date: 1-Nov-2021.Saad F, Fleshner N, Pickles T, Niazi T, Lukka H, Pouliot F, Martins I and Klotz L (2020) Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate CancerJournal of Urology, VOL. 204, NO. 3, (416-426), Online publication date: 1-Sep-2020.Taneja S (2017) Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerJournal of Urology, VOL. 199, NO. 1, (26-28), Online publication date: 1-Jan-2018. Volume 199Issue 1January 2018Page: 251-256Supplementary Materials Advertisement Copyright & Permissions© 2018 by American Urological Association Education and Research, Inc.Keywordsandrogen antagonistsprostatic neoplasmstestosteronecastrationprognosisMetricsAuthor Information Rashid K. Sayyid Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada Department of Surgery, Section of Urology, Medical College of Georgia, Augusta University, Augusta, Georgia More articles by this author Abdallah K. Sayyid Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Zachary Klaassen Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada Department of Surgery, Section of Urology, Medical College of Georgia, Augusta University, Augusta, Georgia More articles by this author Kamel Fadaak Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Hanan Goldberg Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Thenappan Chandrasekar Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Ardalanejaz Ahmad Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Ricardo Leao Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Nathan Perlis Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Karen Chadwick Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Robert J. Hamilton Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Girish S. Kulkarni Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Antonio Finelli Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Alexandre R. Zlotta Department of Urology, Mt. Sinai Hospital, Toronto, Ontario, Canada More articles by this author Neil E. Fleshner Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Expand All Advertisement PDF downloadLoading ...
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
壮观的思远完成签到,获得积分10
1秒前
冷傲悟空发布了新的文献求助10
2秒前
3秒前
大猪完成签到 ,获得积分10
4秒前
文艺点点完成签到,获得积分10
4秒前
顾矜应助guanze采纳,获得10
4秒前
充电宝应助结实的凉面采纳,获得10
4秒前
Galaxy发布了新的文献求助10
5秒前
5秒前
5秒前
科研通AI5应助18101306689采纳,获得10
8秒前
Jane发布了新的文献求助10
9秒前
9秒前
9秒前
10秒前
张玉发布了新的文献求助10
10秒前
16秒前
17秒前
纯真寻冬发布了新的文献求助10
17秒前
Christine完成签到,获得积分20
17秒前
18秒前
18秒前
酶没美镁发布了新的文献求助10
20秒前
bkagyin应助热情的果汁采纳,获得10
20秒前
elephant51发布了新的文献求助10
22秒前
今后应助小周采纳,获得10
22秒前
白瑾完成签到 ,获得积分10
23秒前
量子星尘发布了新的文献求助10
24秒前
ll应助jackmilton采纳,获得10
25秒前
26秒前
26秒前
FanFan应助动听的琴采纳,获得30
27秒前
28秒前
18101306689完成签到,获得积分10
29秒前
29秒前
结实寄柔应助机灵非笑采纳,获得10
30秒前
dingyu24发布了新的文献求助10
30秒前
4466完成签到,获得积分10
30秒前
31秒前
guanze发布了新的文献求助10
31秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971655
求助须知:如何正确求助?哪些是违规求助? 3516320
关于积分的说明 11181963
捐赠科研通 3251445
什么是DOI,文献DOI怎么找? 1795889
邀请新用户注册赠送积分活动 876131
科研通“疑难数据库(出版商)”最低求助积分说明 805266